Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP).

In CRSwNP patients, combined ESS and biologic therapy results in a significant and sustained decrease in polyp burden compared to biologic therapy alone. Larger studies are warranted to further examine the impact of combined therapy. This article is protected by copyright. All rights reserved.